Anzeige
Meldung des Tages: 200 % Upside und Rohstoff-Engpass: Entsteht hier der nächste Versorgungs-Gigant?

Biogen News

Aktie
WKN:  789617 ISIN:  US09062X1037 US-Symbol:  BIIB Branche:  Pharmazeutika Land:  USA
175,19 $
-0,23 $
-0,13%
149,81 € 07.04.26
Depot/Watchlist
Marktkapitalisierung *
22,04 Mrd. €
Streubesitz
3,72%
KGV
11,76
Nachhaltigkeits-Score
49 %
Index-Zuordnung
Nasdaq 100
Weiter abwärts? Short handeln - Jetzt mit Hebel 9,33: VJ92NK
Werbung

Biogen News

30.07.25 - PR Newswire
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-​irmb) Therapy New Clinical Data Presented at AAIC PR Newswire
25.07.25 - GlobeNewswire
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European ...
22.07.25 - GlobeNewswire
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
Lecanemab presentations to include long-term Clarity AD data, real-​world treatment insights, and a subcutaneous formulation for continued care Presentations on tau to explore its ...
10.07.25 - GlobeNewswire
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 –
30.06.25 - GlobeNewswire
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN) There are ...
27.06.25 - GlobeNewswire
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of ...
25.06.25 - GlobeNewswire
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim ...
22.06.25 wallstreetONLINE Redaktion
Blockbuster-Kandidaten: 14 Aktien & 2 ETFs mit Milliardenpotenzial, die wie Bill Gates Alzheimer angehen
Viele forschende Pharmaunternehmen arbeiten intensiv an neuen Alzheimer-​Mitteln, die in den kommenden Jahren auf den Markt kommen könnten. Dies sind die ...
18.06.25 - GlobeNewswire
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to BRAVE study will explore the potential of omaveloxolone to address the critical ...
17.06.25 wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Alle Analysten-Augen auf: Biogen, Etsy, Westwing, Bike24, FMC und AdCapital
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
12.06.25 - GlobeNewswire
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed ...
27.05.25 - GlobeNewswire
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Collaboration leverages City Therapeutics’ next-​generation RNAi engineering technologies and Biogen’s extensive drug development expertise
01.05.25 wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Heute: Börsen Öffnungszeiten sowie Zahlen von Apple, Mastercard & McDonald's
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
16.04.25 - GlobeNewswire
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s ...
15.04.25 - dpa-AFX
ROUNDUP: EU-Kommission lässt Wirkstoff von Biogen und Eisai gegen Alzheimer zu
Die Europäische Kommission hat erstmals eine Alzheimer-​Therapie zugelassen, die auf zugrundeliegende Krankheitsprozesse abzielt. Der Antikörper Lecanemab sei für eine ...
15.04.25 - dpa-AFX
EU-Kommission lässt Wirkstoff Lecanemab von Biogen und Eisai gegen Alzheimer zu
Die Europäische Kommission hat erstmals eine Alzheimer-​Therapie zugelassen, die auf zugrundeliegende Krankheitsprozesse abzielt. Der Antikörper Lecanemab sei für eine ...

Newssuche

Videos

newspaper
07.04.26 +51,46%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »